{"entity":{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","aka":["B7-H4","B7H4","B7x","B7S1","V-set domain containing T cell activation inhibitor 1"],"tldr":"B7-H4 is a checkpoint-like protein that many breast, ovarian and endometrial tumours carry on their surface. Antibody-drug conjugates such as puxitatug samrotecan and HS-20089 use it as a docking site to deliver a chemotherapy payload.","summary":"VTCN1 (chromosome 1p13.1-p12) encodes B7-H4, a ligand that negatively regulates T-cell-mediated immunity by inhibiting T-cell activation, proliferation, cytokine production and the development of cytotoxicity; on tumour macrophages it works with regulatory T cells to suppress tumour-antigen-specific T-cell immunity, and it promotes epithelial cell transformation (UniProt Q7Z7D3). In OnCo it is the surface target of two topoisomerase I payload antibody-drug conjugates: puxitatug samrotecan, in triple-negative breast, ovarian and endometrial cancer, and HS-20089, a humanised IgG1 with a protease-cleavable linker and a drug-to-antibody ratio of about 6, in phase 3 for ovarian and endometrial cancer.","asOf":"2026-09-22","links":[{"label":"HGNC HGNC:28873","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:28873"},{"label":"UniProt Q7Z7D3","url":"https://www.uniprot.org/uniprotkb/Q7Z7D3/entry"},{"label":"NCBI Gene 79679","url":"https://www.ncbi.nlm.nih.gov/gene/79679"}],"tags":["wave5-target"],"related":["top1"],"cancers":["tnbc","ovarian","endometrial"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["puxitatug-samrotecan","hs-20089"],"companies":[],"institutions":[],"pathways":["pd1-checkpoint","immune-desert-exclusion"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Prevalence not recorded in this wave: HGNC and UniProt carry no positivity rates and no other source was consulted."],"provenance":{"editedBy":"OnCo content wave 5 (HGNC REST, UniProt REST, corpus drug and pathway records)","editedOn":"2026-09-22"},"symbol":"VTCN1","hgnc":"HGNC:28873","ensembl":"ENSG00000134258","uniprot":"Q7Z7D3","entrez":"79679","biology":"The puxitatug samrotecan record calls B7-H4 a checkpoint-like protein enriched in breast, ovarian and endometrial cancers; in the corpus it is used as an ADC address rather than as a checkpoint to block.","whereFound":["Triple-negative breast cancer","Ovarian and endometrial cancer","Tumour-associated macrophages"],"targetClass":"checkpoint","prevalence":[]},"route":"/targets/b7h4/","neighbours":{"target":[{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/"}],"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/"},{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/"}],"pathway":[{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/"},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/"}]}}